Barclays »

Lyell Immunopharma shares owned by Barclays

Quarter-by-quarter ownership of Lyell Immunopharma (LYEL) shares owned by Barclays from 13F filings

Historical chart of Barclays investment in Lyell Immunopharma

Tip: Access up to 7 years of quarterly data

All positions including Lyell Immunopharma held by Barclays consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Lyell Immunopharma by Barclays

Quarter filed Position value Share count Share price at filing
2025-09-30 $19k 1.2k 16.24
2025-06-30 $10k 1.2k 8.66

More positions owned by Barclays

Microsoft Corporation (MSFT)
SPDR S&ampP 500 ETF TR Fund (SPY)
Invesco Qqq Tr Fund (QQQ)
NVIDIA Corporation (NVDA)
Ishares Tr Fund (IWM)
Apple (AAPL)
Tesla Opt Put Option (TSLA)
Amazon Opt Call Option (AMZN)
Alphabet Opt Call Option (GOOGL)
Broadcom Opt Call Option (AVGO)
Facebook Inc cl a (META)
Ishares Tr Opt Call Option (HYG)
JPMorgan Chase & Co. (JPM)
Alphabet Opt Put Option (GOOG)
Berkshire Hathaway Inc Del Opt Put Option (BRK.B)

View all positions for Barclays

Top funds holding Lyell Immunopharma

Arch Venture Corp
MWG Management
Foresite Capital Management IV
Vanguard Group
Orland Properties
Almitas Capital
Foresite Capital Management V
venBio Partners
Citadel Advisors
Alphabet
BlackRock
Sc China Holding
Geode Capital Management
Millennium Management
Rbf Capital

View all funds holding Lyell Immunopharma